Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck Foundation, led by CEO Senator Dr. Rasha Kelej, is dedicated to empowering women and youth in science and education in ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Recent health news highlights include Gilead's upbeat 2025 forecast, Edwards Lifesciences surpassing profit estimates, New ...

DIA, a global multidisciplinary life sciences membership association, will bring together thousands of stakeholders from all ...

Reacting to press reports, Germany’s Merck KGaA has confirmed it is in advanced discussions with SpringWorks Therapeutics with the aim of acquiring the US biotechnology company.

KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel miniprotein therapeutics, today announced the appointment of Dr. Philip E. Brandish, PhD as Chief Development ...

KGaA said it is in advanced discussions regarding a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical firm specializing in rare diseases and cancer treatments.

The US Food and Drug Administration approved Gomekli (mirdametinib), from SpringWorks Therapeutics, a kinase inhibitor, for adult and pediatric patients two years of age and older with ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...